| Literature DB >> 28708900 |
Jenniffer Angulo1, Constanza Martínez-Valdebenito2, Claudia Marco2, Héctor Galeno3, Eliecer Villagra3, Lilian Vera3, Natalia Lagos3, Natalia Becerra3, Judith Mora3, Andrea Bermúdez4, Janepsy Díaz4, Marcela Ferrés2, Marcelo López-Lastra1.
Abstract
Andes virus (ANDV) is the etiological agent of hantavirus cardiopulmonary syndrome in Chile. In this study, we evaluated the profile of the pro-inflammatory cytokines IL-1β, IL-12p70, IL-21, TNF-α, IFN-γ, IL-10 and IL-6 in serum samples of ANDV-infected patients at the time of hospitalization. The mean levels of circulating cytokines were determined by a Bead-Based Multiplex assay coupled with Luminex detection technology, in order to compare 43 serum samples of healthy controls and 43 samples of ANDV-infected patients that had been categorized according to the severity of disease. When compared to the controls, no significant differences in IL-1β concentration were observed in ANDV-infected patients (p = 0.9672), whereas levels of IL-12p70 and IL-21 were significantly lower in infected cases (p = <0.0001). Significantly elevated levels of TNF-α, IFN-γ, IL-10, and IL-6 were detected in ANDV-infected individuals (p = <0.0001, 0.0036, <0.0001, <0.0001, respectively). Notably, IL-6 levels were significantly higher (40-fold) in the 22 patients with severe symptoms compared to the 21 individuals with mild symptoms (p = <0.0001). Using multivariate regression models, we show that IL-6 levels has a crude OR of 14.4 (CI: 3.3-63.1). In conclusion, the serum level of IL-6 is a significant predictor of the severity of the clinical outcome of ANDV-induced disease.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28708900 PMCID: PMC5529019 DOI: 10.1371/journal.pntd.0005757
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Characteristic of andes virus-infected patients (n = 43).
| Variable | Patients, No. (%) |
|---|---|
| Male [n (%)] | 26 (60.5) |
| Female [n (%)] | 17 (39.5) |
| 33 ±14 | |
| 0–15 [n (%)] | 3 (7.0) |
| 16–30 [n (%)] | 15 (34.9) |
| 31–50 [n (%)] | 19 (44.1) |
| 51–80 [n (%)] | 6 (14.0) |
| North (17º30’ to 32º16’) [n (%)] | 1 (2.3) |
| Center (32º02’to 36º33’) [n (%)] | 8 (18.6) |
| South (36º00’ to 56º30’) [n (%)] | 34 (79.1) |
| Area of infection [n (%)] | |
| Urban area | 3 (7.5) |
| Rural area | 37 (92.5) |
| Mild [n (%)] | 21 (48.8) |
| Severe [n (%)] | 22 (51.2) |
| Total Lethality [n (%)] | 14 (32.5) |
Abbreviation: SD, Standard deviation.
a 40 patients with available data.
b Including the 14 deceased patients.
Available clinical and laboratory findings at the time of sample collection.
| Variable | Patients, No. (%) | P value | |
|---|---|---|---|
| Severe | Mild | ||
| 22 (100.0) | 19 (90.5) | 0.2326 | |
| 16 (72.7) | 16 (76.2) | 0.5360 | |
| 20 (90.9) | 18 (85.7) | 0.4771 | |
| 18 (81.8) | 18 (85.7) | 0.5274 | |
| 22 (100.0) | 12 (57.1) | ***0.0005 | |
| 19 (86.4) | 15 (71.4) | 0.2043 | |
| 6 (27.3) | 2 (9.5) | 0.1350 | |
| 2 (10.5) | 1 (4.8) | 0.4615 | |
| 19 (86.4) | 19 (90.5) | 0.5229 | |
| 12 (54.5) | 5 (23.8) | *0.0394 | |
a Classified according to clinical outcome.
b Defined as >10% atypical lymphocytes.
c Available data for 19 severe patients.
d Defined as < 150.000 mm3.
e Defined as >52% for men and >48% for women.
Fig 1IL-1β, IL-12p70, and IL-21 levels in control and ANDV-infected patients.
Circulating levels of cytokines (A) IL-1β, (B) IL-12p70 and (C) IL-21 in serum samples of Control individuals and ANDV-infected patients with Mild or Severe disease progression are represented by dots. IL-1β and IL-12p70 were expressed in pg/mL while the circulating levels of IL-21 are expressed as Log10 (pg/mL) to facilitate comparison between the groups. A Mann-Whitney test for continuous variables was performed to evaluate significant differences between Controls and Mild or Severe, and Severe versus Mild groups. The ends of the brackets indicate the compared groups. The dashed line represents the lower limit of detection. Each serum sample was analyzed in duplicate in the same plate.
Fig 2TNF-α, IFN-γ, IL-10, and IL-6 levels in control and ANDV-infected patients.
Circulating levels of cytokines (A) TNF-α, (B) IFN-γ, (C) IL-10, and (D) IL-6 in serum samples of Control individuals and ANDV-infected patients with Mild or Severe disease progression are represented by dots. Each value expressed in pg/mL was transformed to Log10 (pg/mL) to facilitate comparison between the groups. A Mann-Whitney test for continuous variables was performed to evaluate significant differences between Controls and Mild or Severe, and Severe versus Mild groups. The dashed line represents the lower limit of detection. The ends of the brackets indicate the compared groups. Each serum sample was analyzed in duplicate in the same plate.
Cytokine concentration in serum of controls and ANDV-infected patients.
| ANDV-Infected Patients | ||||
|---|---|---|---|---|
| Total | Mild Disease | Severe Disease | ||
| 3.49 (2.5–33.94) | 4.60 (2.5–64.62) | 3.84 (2.5–26.06) | 5.32 (2.5–64.62) | |
| 21.86 (1.84–104.31) | 5.43 (1.84–51.26) | 7.28 (1.84–51.26) | 3.67 (1.84–27.88) | |
| 74.23 (2.37–303.0) | 16.75 (2.37–186.5) | 21.57 (2.37–186.5) | 12.14 (2.37–119.5) | |
| 21.55 (2.90–85.35) | 70.05 (15.87–407) | 61.01 (17.18–144.5) | 78.68 (15.87–407) | |
| 31.38 (4.95–183.0) | 69.62 (4.95–652.0) | 50.21 (4.95–183.0) | 88.13 (5.99–652.0) | |
| 5.74 (4.5–45.49) | 133.21 (4.5–776.0) | 129.85 (4.5–776.0) | 136.25 (4.5–347.0) | |
| 7.84 (3.34–105.64) | 411.94 (3.34–10281.8) | 19.47 (3.34–75.66) | 786.57 (3.34–10281.8) | |
a Classified according to clinical outcome.
Fig 3Serum levels of IL-6 in control, HCPS survivals or fatal cases.
Circulating levels of IL-6 in serum samples of control individuals and HCPS survivors or fatalities are represented by dots. Values are expressed in Log10 (pg/mL). A Mann-Whitney test for continuous variables was performed to evaluate significant differences between controls individuals and HCPS survivors or fatalities. The ends of the brackets indicate the compared groups. The dashed line represents the lower limit of detection. Each serum sample was analyzed in duplicate in the same plate.
Cytokine concentration in serum of survivors or deceased ANDV-infected patients.
| ANDV-Infected Patients | ||||
|---|---|---|---|---|
| Total | Survivals | Fatal cases | P value | |
| 4.60 (2.5–64.62) | 3.48 (2.5–26.06) | 6.94 (2.5–64.62) | >0.9999 | |
| 5.43 (1.84–51.26) | 5.96 (1.84–51.26) | 4.35 (1.84–27.88) | 0.7508 | |
| 16.75 (2.37–186.5) | 17.36 (2.37–186.5) | 15.48 (2.37–119.5) | 0.5314 | |
| 70.05 (15.87–407) | 61.75 (17.18–144.5) | 87.26 (15.87–407) | 0.6521 | |
| 69.62 (4.95–652.0) | 81.85 (4.95–652) | 44.27 (5.99–93.57) | 0.8880 | |
| 133.21 (4.5–776.0) | 128.40 (4.5–776.0) | 143.22 (4.5–347.0) | 0.3618 | |
| 411.94 (3.34–10281.8) | 41.59 (3.34–285) | 1179.08 (13.075–10281.8) | **** <0.0001 | |
a Classified according to clinical outcome.
Logistic regression of clinical and cytokine level variables.
| ORmodel 1 | ORmodel 2 | |||||
|---|---|---|---|---|---|---|
| 1.0 | - | |||||
| 1.2 | 0.3–4.7 | |||||
| 0.6 | 0.1–4.1 | |||||
| 1.3 | 0.3–6.8 | |||||
| 1.0 | - | 1.0 | - | 1.0 | - | |
| 0.4 | 0.1–1.8 | |||||
| 0.3 | 0.1–1.6 | |||||
| 2.2 | 0.2–26 | |||||
| 1.5 | 0.2–10 | |||||
| 3.8 | 1–14.2 | 6.9 | 0.8–54.9 | |||
| 0.4 | 0.4–5.4 | |||||
| 0.3 | 0.3–3.0 | |||||
| 0.5 | 0.1–2.4 | |||||
| 1.6 | 0.5–5.7 | |||||
| 1.4 | 0.4–4.8 | |||||
| 2.0 | 0.6–6.9 | |||||
| 14.4 | 3.3–63.1 | 10 | 1.6–74.7 | 10.9 | 1.6–74.7 |
a OR not calculated because one or more boxes contain zero.
* Significant
OR model 1: Stepwise Forward
OR model 2: Stepwise Reverse